Drug Type AAV based gene therapy |
Synonyms- |
Target |
Mechanism ELOVL2 gene transference(ELOVL fatty acid elongase 2 gene transference) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Visgenx, Inc.Startup |
Active Organization Visgenx, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
dry age-related macular degeneration | Preclinical | US | Visgenx, Inc.Startup | 07 Apr 2024 |